In the evolving landscape of biochemical research, the exploration of small-molecule compounds has opened new avenues for understanding cellular signaling. Among these, azelaprag peptide (often categorized as AMG 986) has garnered significant attention within the scientific community. As a researcher and enthusiast of peptide-based studies, I have closely followed the discourse surrounding this compound, particularly its role as an apelin receptor Azelaprag - TargetMol Chemicals Inc agonist.
Understanding the Compound
Azelaprag is a candidate active molecule for an Apelin receptor agonist, distinguished by its high binding Aug 21, 2024—Azelapragis under investigation in clinical trial NCT06515418(Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared affinity. With an EC50 of 0.32 nM for the apelin receptor, it represents a potent tool for those investigating the APJ pathway. From a technical perspective, the substance is often supplied as a high-purity biochemical inhibitor, which is essential for ensuring consistency in laboratory settings.
When reviewing the chemical properties, it is im azelaprag | Ligand page portant to note the following:
* CAS Number: 2049980-18-7
It was originally developed as a potential treatment for heart failure and has subsequently been investigated for other applications such as obesity and muscle Read more* Molecular Formula: C25H29N7O4S
* Molecular Weight: 523.61
Many researchers look for this product under the moniker "Product Name: Azelaprag," ensuring that the batch meets high- BioAge shares tumble after decision to halt obesity drug purity standards, often exceeding 98% or 99% HPLC purity.
The Role of the Apelin Receptor
Azelaprag mimics the activity of the exerkine apelin, a peptide that is n Product Name. Azelaprag, Inhibitor; Full Product Name. Azelaprag ; Research Use Only. For Research Use Only. Not for use in diagnostic procedures. ; MBS5768480 Read more aturally released in response to exercise. Because azelaprag acts as a potent agonist of the apelin receptor (APJ), it has been the subject of intense scrutiny regarding its potential to influence skeletal muscle and metabolic function.
In my own review of the available literature, it is fascinating to see how the compound is described not just as a chemical entity, but as a mechanism to study systemic responses. It is an apelin receptor agonist agent candidate that has, at various stages, been considered for its potential to improve cardiac contractility in preclinical models without adversely impacting hemodynamics.
Research Context and Developments
The research trajectory for this compound has been dynamic. While BioAge L Azelapragcan be used to treat nervous system diseases, cardiovascular diseases. abs on Friday announced that it is discontinuing the Phase II STRIDES study due to internal strategic decisions and safety considerations, the scientific utility of the molecule remains a topic of interest.
Historically, this compound has been explored for its potential as an oral regimen to amplify weight loss and restore body composition. Many investigators were specifically interested in the efficacy of azelaprag in combination with tirzepatide for treating obesity, a protocol that was under investigation in clinical trial NCT06515418. While clinical trials represent one facet of its history, the core of the molecule's value lies in its role as an effective small-molecule apelin receptor agonist for fundamental research.
Potential Applications in Laboratory Settings
Beyond the scope of metabolic studies, azelaprag is frequently cited in research focused on:
* Cardiovascular health: AMG 986 is a novel apelin receptor (APJ) agonist that has demonstrated significant cardioprotective effects in specific experimental models.
* Neurological pathways: The compound is often studied for its potential applications in the treatment of neurological and cardiovascular diseases.
As a laboratory tool, it is categorized as a "Product Name: Azelaprag, Inhibitor" in some catalogs, intended strictly for research use. Whether one is sourcing it for an apelin receptor agonist study or examining its ability to influence muscle function, the consensus is that it remains a critical reference point for those studying the G-protein coupled receptor (GPCR) family.
Final Reflections
Engaging with such specialized compounds requires a deep understanding of their biochemical profile. Because azelaprag mimics the activity of the exerkine apelin, it serves as a bridge for researchers trying to isolate the effects of exercise-induced signaling. While the news that Azelaprag (AMG 986) | Apelin Receptor Agonist BioAge Labs on Friday announced that it is discontinuing the Phase II STRIDES study may have shifted the commercial focus, the academic pursuit of understanding how this molecule contributes to increased weight loss and improved metabolic markers continues in laboratories worldwid Dec 6, 2024—The Company has made the decision to discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidateazelapragas monotherapy and in Read more e.
For those navigating the complexities of purchasing or utilizing this peptide, always prioritize verified sources that provide detailed HPLC documentation, ensuring the compound remains a high-purity biochemical inhibitor for your specific research applications.